Sage Therapeutics, Inc.: 10-Q filed 2024-07-31
What Sage Therapeutics, Inc. reported in its quarterly report filed 2024-07-31 (fiscal Q2 2024): 36 published measures, 102 facts as tagged in accession 0000950170-24-088593.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-07-31
- Fiscal period
- fiscal Q2 2024
- Accession
- 0000950170-24-088593 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Sage Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 697,105,000 | USD | |
| At 2023-12-31 | 882,277,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 69,043,000 | USD | |
| At 2023-12-31 | 82,747,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 628,062,000 | USD | |
| At 2024-03-31 | 705,801,000 | USD | |
| At 2023-12-31 | 799,530,000 | USD | |
| At 2023-06-30 | 984,376,000 | USD | |
| At 2023-03-31 | 1,133,129,000 | USD | |
| At 2022-12-31 | 1,252,599,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 99,901,000 | USD | |
| At 2023-12-31 | 70,992,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -102,854,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -211,337,000 | USD | 182 |
| 2024-01-01 to 2024-03-31 | -108,483,000 | USD | 91 |
| 2023-04-01 to 2023-06-30 | -160,325,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -307,153,000 | USD | 181 |
| 2023-01-01 to 2023-03-31 | -146,828,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -118,269,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -285,200,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 0 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 337,000 | USD | 181 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 8,654,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 16,556,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 2,474,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 5,768,000 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 9,628,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 3,519,000 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 139,050,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 240,460,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -2,780,996,000 | USD | |
| At 2023-12-31 | -2,569,659,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 60,538,319 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 60,337,258 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 59,769,640 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 59,722,147 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 60,538,319 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 60,337,258 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 59,769,640 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 59,722,147 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -1.7 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -3.5 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -2.68 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -5.14 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -1.7 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -3.5 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -2.68 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -5.14 | USD/shares | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,274,000 | USD | |
| At 2023-12-31 | 1,921,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 30,865,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 31,731,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -111,300,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -228,973,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -170,457,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -325,927,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 686,811,000 | USD | |
| At 2023-12-31 | 869,350,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 69,043,000 | USD | |
| At 2023-12-31 | 82,747,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 8,650,000 | USD | |
| At 2023-12-31 | 10,318,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 9,943,000 | USD | |
| At 2023-12-31 | 83,009,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 119,954,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 245,529,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 172,931,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 331,695,000 | USD | 181 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 55,983,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 108,556,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 75,565,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 141,273,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 62,564,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 134,297,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 97,161,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 189,987,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 60,894,934 | shares | |
| At 2023-12-31 | 60,043,643 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -691,000 | USD | |
| At 2023-12-31 | -814,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,220,000 | USD | |
| At 2023-12-31 | 4,458,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 7,800,000 | USD | |
| At 2023-12-31 | 6,548,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 58,982,000 | USD | |
| At 2023-12-31 | 67,264,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 28,743,000 | USD | |
| At 2023-12-31 | 31,825,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -211,337,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -307,153,000 | USD | 181 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -102,758,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -211,214,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -160,881,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -302,591,000 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 647,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 654,000 | USD | 181 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 15,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 2,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -41,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -229,000 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -1,668,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -9,566,000 | USD | 181 |
Inspect the source
- Entity
- Sage Therapeutics, Inc. / CIK 0001597553
- Captured
- 2026-09-21T17:20:16.999Z
- SEC response SHA-256
afd97550f2619e8ee699b816b1e9c9bfcb0395cfffc579f5c489401eae3ca58f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001597553.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))